Version 1
: Received: 21 September 2023 / Approved: 21 September 2023 / Online: 22 September 2023 (09:19:28 CEST)
How to cite:
Al-Hilal, H.; Maretina, M.; Egorova, A.; Glotov, A.; Kiselev, A. Quantification of the Number of Nuclear Gems as a Potential Biomarker for Spinal Muscular Atrophy. Preprints2023, 2023091527. https://doi.org/10.20944/preprints202309.1527.v1
Al-Hilal, H.; Maretina, M.; Egorova, A.; Glotov, A.; Kiselev, A. Quantification of the Number of Nuclear Gems as a Potential Biomarker for Spinal Muscular Atrophy. Preprints 2023, 2023091527. https://doi.org/10.20944/preprints202309.1527.v1
Al-Hilal, H.; Maretina, M.; Egorova, A.; Glotov, A.; Kiselev, A. Quantification of the Number of Nuclear Gems as a Potential Biomarker for Spinal Muscular Atrophy. Preprints2023, 2023091527. https://doi.org/10.20944/preprints202309.1527.v1
APA Style
Al-Hilal, H., Maretina, M., Egorova, A., Glotov, A., & Kiselev, A. (2023). Quantification of the Number of Nuclear Gems as a Potential Biomarker for Spinal Muscular Atrophy. Preprints. https://doi.org/10.20944/preprints202309.1527.v1
Chicago/Turabian Style
Al-Hilal, H., Andrey Glotov and Anton Kiselev. 2023 "Quantification of the Number of Nuclear Gems as a Potential Biomarker for Spinal Muscular Atrophy" Preprints. https://doi.org/10.20944/preprints202309.1527.v1
Abstract
Spinal muscular atrophy is a neuromuscular disorder caused by mutationsin both copies of the survival motor neuron gene 1 (SMN1) which lead to reduction in the production of the SMN protein. Currently, there are several therapies that have been approved for SMA, with much more undergoing active research. While various biomarkers have been proposed for assessing the effectiveness of SMA treatment, a universally accepted one still hasnot been identified. This study aimed to investigate whether the number of gems in cell nuclei could serve as a potential biomarker for SMA. To gain insight into whether the number of gems in cell nuclei varies based on their SMN genotype and whether the increase in gems number is associated with therapeutic response, we utilized fibroblast cell cultures obtained from a patient with SMA type II and from healthy individual. We have discovered a remarkable difference in the number of gems found in the nuclei of these cells, specifically when counting gems per 100 nuclei. Then the SMA fibroblasts were treated with antisense oligonucleotides the beneficial effects in correcting the abnormal splicing of SMN2 exon 7 have been demonstrated. It was observed that there was a significant increase in the number of gems in the treated cells compared to the intact SMA cells. The results obtained significantly correlate with an increase of full-length SMN transcripts share. Based on our findings, it is evident that the quantity of gems can be regarded as a reliable biomarker for SMA drugs development.
Medicine and Pharmacology, Neuroscience and Neurology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
